Business Context and Reporting Period
This Form 6-K filing by NovaBridge Biosciences covers the month of June 2026. The report primarily addresses significant changes in executive leadership and the Board of Directors effective July 1, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding management changes and does not contain financial statements or performance metrics.
Material Changes
- CEO Transition: Srishti Gupta, MD MPP, was appointed Chief Executive Officer and Board member, effective July 1, 2026. She succeeds Xi-Yong (Sean) Fu, who resigned as CEO and Board member effective June 30, 2026.
- Board Resignations: Emmett T. Cunningham, Jr. and Sean Cao resigned from the Board of Directors effective June 30, 2026.
- Executive Role Change: Mark Hagler resigned as President effective July 1, 2026, but will continue as Chief Commercial Officer.
- Advisory Roles: Dr. Fu will serve in an advisory capacity during the transition, and Dr. Cunningham will join the Scientific Advisory Board.
Outlook, Risks, and Commentary
Management commentary indicates that all resignations were not the result of any disagreement with the Company regarding operations, policies, or practices. The filing highlights Dr. Gupta's extensive background, including her recent role as CEO of Idorsia Pharmaceuticals and her decade-long leadership of the Global Health Practice at McKinsey & Company. No specific financial guidance, risks, or contingencies are detailed in this document.
Key Facts for Investor Verification
- Verify the effective date of Dr. Gupta's appointment as CEO (July 1, 2026).
- Confirm the status of the Board of Directors following the resignations of Dr. Fu, Dr. Cunningham, and Mr. Cao.
- Review the attached press release (Exhibit 99.1) for additional details on the strategic rationale for the leadership change.
- Note that this filing does not contain updated financial data; investors should refer to the most recent Form 20-F for financial performance.